Eyenovia, Inc. Stock price
Is Eyenovia, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.
Key metrics
Eyenovia, Inc. Stock Analysis
Analyst Opinions
8 Analysts have issued a Eyenovia, Inc. forecast:
Analyst Opinions
8 Analysts have issued a Eyenovia, Inc. forecast:
Don't miss a Thing! We will send you all news about Eyenovia, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.
| Head office | United States |
| CEO | Mr. Rowe |
| Employees | 14 |
| Founded | 2014 |
| Website | eyenovia.com |


